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ABSTRACT
The myelodysplastic syndrome (MDS) is a rare, clonal disorder of pluripotent stem cells in children and is
characterized by ineffective haematopoiesis, morphologic abnormalities in one or more cell lines in a usually
cellular bone marrow, and by predilection for the acute leukaemia. A large proportion of children with MDS
present associated clinical abnormalities. Allogeneic stem cell transplantation (SCT) is the only definitive cure for
this heterogeneous group of lethal disorders. Results with SCT have been difficult to interpret due to the variability
of conditioning regimens, types of donors, and pretransplant therapy. In many series, the outcome with donors
other than matched siblings has been extremely poor. The optimal pre-transplant therapy and conditioning
regimen for SCT in MDS have not yet been defined. The establishment of several international working groups
will eventually help to elucidate the pathogenesis of childhood MDS and will evaluate new treatment strategies to
improve their clinical outcome.
CLASSIFICATION, ETIOPATHOGENESIS
The myelodysplastic syndrome (MDS)
accounts 5-10% of all malignant
haematological disorders in children [1]. This
rare disease is composed of a heterogeneous
group of clonal stem cell disorders,
characterized by ineffective haematopoiesis
with evident morphological abnormalities.
Blood cytopaenia often involves all three
lineages with morphologically and funcionally
abnormal cells. The bone marrow is usually
hypercellular, and displays characteristic
dysplastic features, often with an increased
percentage of myeJoblasts. The French-
American-British group (FAB) proposed a
classification of MDS comprising five
subgroups: refractory anaemia (RA), RA with
ringed sideroblasts(RARS), RA with excess of
blasts (RAEB), RAEB in transformation
(RAEBt), and chronic myelomonocytic
leukaemia (CMML) [2]. In children, the term
CMML was replaced by the term 'juvenile
myelomonocytic leukaemia (JMML)'. The
distinction between the subgroups is based
upon the number of blasts and monocytes in
the blood, the number of ringed sideroblasts
and blasts in the bone marrow, and the
presence of Auer rods. With a few exceptions,
the FAB classification can be successfully
applied to childhood cases.
Today evidence has accumulated to support
the concept that MDS is not only, preleukaemic
phase of acute myelogenous leukaemia (AML),
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but it also represents a distinct haematological
disorder, as reflected in different responss to
therapy in MDS and AML. MDS involves
pluripotent stem cells, whereas AML often
involves more mature progenitor cells.
Differences in cytogenetics and in the
response to therapy between MDS and AML,
reflecting fundamental biological differences,
and thus justifies the morphologically based
distinction between the two conditions
proposed by the FAB group. Cases with blast
counts close to 30%, whether classified as
RAEBt or AML, may be quite similar from the
biological point of view. Cases with a low blast
cell count and AML-specific translocations may
fit better a classification of AML, and should be
treated as de novo AML [3].
There seem to exist major differences
between childhood and adult MDS.
RAEB/RAEBt and JMML dominate in
childhood, whereas RARS, being common in
older adults, is extremely rare in childhood. RA
in children appears to have a higher rate of
progression to leukaemia and a shorter time to
progression. Monosomy 7 is the abnormality
most frequently found in children. Predisposing
conditions are more frequent in children than
they are in adults. Most children transform to a
more aggressive form of MDS or to AML within
the first year following presentation. Children
with RA may have a stable clinical condition
lasting several years before progression.
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CYTOGENETICS
Cytogenetic abnormalities of the bone
marrow cells are found in the majority of
patients with MDS. Monosomy 7 is by far the
most commonly encountered abnormality in
children, whereas translocations, unlike in
AML, are uncommon. Trisomy 8 is the second
most common abnormality. Sequential
cytogenetic examinations are recommended
because clonal evolution is frequently
encountered during the progression of the
disease. Monosomy 7, as the sole abnormality
in children, is apparently associated with a
relatively long median survival. A stable
disease lasting several years was documented
in more than half of the patients with RA or
RAEB and monosomy 7 [4]. Children with
monosomy 7 alone had a superior survival rate
than those with monosomy 7 and other
cytogenetic abnormalities. The reverse was
found in AML with monosomy 7 alone (3-y
survival 13%) [4].
PREDISPOSING CONDITIONS
At least one third of the children who develop
any form of MDS - suffer from genetically
predisposing syndromes, whereas secondary
and therapy-related forms of MDS are
comparatively rare.
The risk of AML or MDS is approximately
10% in childen with severe aplastic anaemia
not treated with stem cell transplantation (SCT)
and approximately 7,5% in children with severe
forms of congenital neutropenia at least 48
months from the diagnosis and G-CSF
administered for a period of 24 months (5). It
was especially MDS associated with
monosomy 7 that has been fully documented.
Familial bone marrow monosomy 7 has
been observed in at least 10 kindreds.
Clinicians should always be aware of the
possibility that a child with MDS or AML and
monosomy 7 may be the first one in an
affected family. Therefore, potential sibling
donors have to be carefully evaluated before
they are eligible for SCT.
AML in children with the Down syndrome
may be preceded by MDS in 30 to 60% of
cases. MDS in children with the Down
syndrome is, unlike MDS in other children,
frequently associated with isolated
thrombocytopenia as the presenting feature,
and trisomy 8 as the most common acquired
cytogenetic abnormality. MDS in the Down
syndrome occurs virtually always during the
first four years of life. AML that evolves from
MOS in children with the Down syndrome
responds very well to chemotherapy [6].
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MDS was reported in 5-10% and AML in
10% of patients with Fanconi anaemia. RA and
RAEB have been predominantly associated
with this DNA repair deficiency syndrome.
Fanconi anaemia should be excluded at the
diagnosis of MOS. In the case of SCT a
reduced-intensity conditioning regimen should
be used due to a high risk of post-transplant
toxicity in these patients.
Children with neurofibromatosis type 1
account for approximately 15% of children with
JMML.
THERAPY
The treatment options of childhood MOS are
at present very limited. Treatment with
intensive chemotherapy (AML protocols) is
associated with a high rate of cytopenia related
deaths and a low remission rate. Those with
remission often relapse within two years (7).
With the exception of children with the Down
syndrome there is only anecdotal evidence for
the cure of MDS by intensive chemotherapy
not followed by SCT. Conventional
chemotherapy is apparently unlikely to
eradicate primitive pluripotent cells involved in
MOS, rendering the therapy non-curative.
Consequently, myeloablative therapy
supported by an allogeneic stem cell infusion
may be necessary to cure childhood MDS.
With very few exceptions SCT seems be the
only curative treatment. More children than
adults are likely to benefit from SCT. SeT is
associated with a survival rate of 30 - 60%:>.
The high rate of relapse in advanced FAB
stages has led to graft patients earlier in the
course of the disease. Patients with RA, RAEB
or JMML and monosomy 7 treated with SCT
without prior chemotherapy had a 3-year
survival rate of 73% [4].
STEM CELL TRANSPLANTATION FOR JMML
JMML - a disorder with myeloproliferative
features primarily observed in infancy and
early childhood - is characterized by prominent
hepatosplenomegaly, frequent skin
involvement, leukocytosis, monocytosis, and
presence of immature precursors in peripheral
blood. It is characterized by a reversion to a
fetal type of erthropoiesis and the spontaneous
exuberant proliferation of neoplastic
macrophage/monocyte progenitor cells in vitro.
The characteristic spontaneous formation of
extremely high numbers of abnormal colony-
forming unit cells (CFU-GM) colonies in vitro
are probably generated through an autocrine
or paracrine production of cytokines, such as
interleukin 1 and GM-CSF. The most important
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pathophysiological feature seems to be the
neoplastic cells hypersensitivity to GM-CSF.
JMML alone accounted for 2-3% of all
leukaemias, and has previously been referred
to as chronic myelomonocytic leukaemia
(CMML) or juvenile chronic myelogenous
leukaemia (JCML). A disease with monosomy
7 has also been referred to as an infantile
monosomy 7 syndrome.
In a large series of patients with JMML, the
median survival rate without SCT was one
year. At 10 years, the probability of survival for
untransplanted patients is 6%. Prognostic
factors for the length of survival without SCT
were the platelet count at the time of diagnosis,
age and HbF. While all patients with a platelet
count < 33x109/1 died within one year after
diagnosis, 70% of the children with a higher
platelet count, age < 2 years and an HbF <
15% were still alive 3 years after diagnosis.
Karyotype did not influence survival
significantly [8].
Most of the children classified as JMML
treated with AML-like schedules did achieve a
remission, but virtually all of them relapsed
within two years. In a retrospective analysis of
treatment modalities other than SCT, the
survival of the intensively treated group was
similar to that of children receiving less
intensive treatment 16-mercaptopurin).
Splenectomy in children without SCT can
significantly prolong survival, while the role of
splenectomy in SCT is less clear. It is current
practice to remove large spleens prior to SCT.
Children with JMML should be transplanted
early in the course of their disease. Highdsk'
patients according to the platelet count, age
and ribF level may be candidates .for an
experimental SCT (haploidentical family
donor), if HLA-identical donor is not readily
available. Good risk patients have sufficient
time to search for an optimal SCT donor. SCT
is capable of curing approximately 30% of
patients, with a significant advantage for those
transplanted using an HLA-compatible family
donor [9,10]. Busulfan-based myeloablative
therapy should be preferred, since it seems
to offer a better EFS due to a greater
antileukaemic activity. Busulfan pharmaco-
kinetics vary with patient's is age, careful
monitoring of busulfan plasma levels should be
carried out in all patients, and especially in
those under 3 years of age. In children with
JMML given allogeneic SCT from HLA-
compatible family donor, a reduction in the
intensity and/or duration of GVHD prophylaxis
can significantly contribute, through an
enhanced antitumour effect, to successful
leukaemia control. Children less than 2 years
of age at SCT had an improved EFS, which
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reproduces the more favourable outcome in
younger patients.
The risk of a relapse has been very high
following SCT. If a relapse occurs, a second
SCT may be curative. Some patients who
relapsed early following matched unrelated
donor (MUD) SCT for JMML, were able to
achieve remission following withdrawal of
immunosuppressive therapy and SUbsequent
development of GVHD, providing evidence of a
graft-versus-Ieukaemia (GVL) effect for JMML
[11]. Immunotherapy including infusions of
donor-derived lymphocytes may also prove
useful in patients who relapse after SCT.
STEM CELL TRANSPLANTATION FOR RA,
RAEB,RAEBT
Most cases of RAEB and RAEBt eventually
progress to AML. While some patients with
RAEB haver stable disease for several
months, others progress to RAEBt and AML
early. The 3-year survival in children not
treated with SCT is approximately 10% [12]. As
most patients with RA will progress to
leukaemia, SCT is the treatment of choice.
SCT should be performed before the blast
count has increased to more then 10%, as
chemotherapy prior to SCT should be avoided.
Dependency on blood product transfusions can
fasten the decision about timing of SCT.
Allogeneic SCT is the treatment of choice for
children if compatible sibling or matched
unrelated donor is available. A greater than
50% event-free survival rate has been
achieved in ,children with· MDS, inclUding RA,
who were transplanted without the pteceding
induction therapy. Patients with RA and stable
RAES are unlikely to benefit from intensive
chemotherapy before SCT, and it is still an
open question whether pre-transplant
chemotherapy would improve the outcome in
patients Who have RAEBt [13,14]. The risk of
transplant-related mortality may be higher in
patients who received intensive chemotherapy
prior to SCT. Patients without excess of blasts
have a superior survival following SCT,
although a 50% survival has been reported
following SCT in previously untreated RAEBt.
There are no randomized studies, which would
compare the results of induction chemotherapy
versus SCT as the first line treatment in MDS.
If no HLA-identical donor is available,
intensive AML-specific chemotherapy seems to
be an option to improve survival without
SCT.Younger age, normal karyotype, RAEBt
morphology, and the presence of Auer rods
are all associated with relatively favorable
results of chemotherapy in adults.
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There appears to be no significant difference
in the outcome based on preparative regimen
in this population of patients [15].
THERAPY-RELATED MDS AND AML
AML preceded by the MOS can be expected
to develop in 3 to 10 percent of patients who
receive alkylating agents as part of their
therapy for primary cancer. The risk of this type
complication peaks 5 to 10 years after the start
of chemotherapy, which is often associated
with deletions of chromosomes 5 and 7. The
prognosis in these patients is considerably
worse than that in patients with primary AML.
Therapy-related AML is biologically more
aggressive and/or more resistant to treatment
than spontaneous AML. Chemotherapy fails to
achieve long-lasting remissions. SCT seems to
offer a better chance for cure but at present the
results are still disappointing [16]. Increased
incidence of severe or moderately severe
regimen-related toxicity is reported in patients
transplanted for secondary AML and MOS.
Patients with therapy-related AML conditioned
with busulfan and cyclophosphamide have a
higher risk of a relapse than do patients with
de novo AML conditioned with the same
agents [17]. Survivors of SCT for therapy-
related leukaemia will be at a significant risk of
developing third malignancies even in the
absence of a familial cancer predisposition.
Non myeloablative conditioning with donor
lymphocyte infusion (OLl) post-transplant
would be a reasonable option for further
evaluation in this group of patients.
CONCLUSIONS
Allogeneic SCT appears to be the only
curative strategy for childhood MOS. Previous
reports on the efficacy of SCT refer to only a
small numbers of patients, treated with a
variety of myeloablative regimens and GVHO
prophylaxis schemes. A busulfan-based
intensive conditioning regimen seems to offer a
better chance for cure in comparison with TBI-
based therapy. Graft-versus-Ieukaemia effect
has an active role in control of MOS. This may
prove important in the design of GVHO
prophylaxis regimens, and suggests that
aggressive treatment of GVHD may increase
the likelihood of a relapse. In addition,
immunotherapy, including infusions of donor-
derived lymphocytes, may also prove useful in
patients who relapse after SCT. Adoption of
more effective methods of selecting unrelated
donors can also improve treatment results.
Further improvements in the ability to treat
patients with this disorder will only be expected
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if patients are treated in a uniform manner in
prospective clinical trials within the context of
large cooperative groups in Europe (EWOG-
MDS) and in North America (CCG/POG).
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